2.99
-1.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adicet Bio
From its filings with the US Securities and Exchange Commission
Adicet Bio is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ACET. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $116.8m. At that date it held total assets of $192.4m and shareholders' equity of $159.2m.
We are a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. We are advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.
Our approach to activate, engineer and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows us to generate new product candidates in a rapid and cost-efficient manner. Our allogeneic "off-the-shelf" manufacturing process is designed to allow product from unrelated donors to be stored and sold on demand to treat patients without inducing a graft versus host immune response. This is in contrast to products based on alpha beta T cells, which either must be manufactured for each patient from his or her own T cells, or require significant gene editing to manufacture if the T cells are derived from donors that are unrelated to the patient.
Our lead product candidate, prulacabtagene leucel (prula-cel, formerly ADI-001), a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. We are also pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA). ADI-212 is engineered to express a novel CAR binder designed to support enhanced tolerability and tumor-specific recognition.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jan 2018
- Employees
- 102
- Website
- adicetbio.com ↗
- Head office
- 131 DARTMOUTH STREET, BOSTON, MA, 02116
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Chen SchorPresident, Chief Executive Officer, Director, since 2022$4.6m
- Mr. Nick HarveyChief Financial Officer$1.5m
- Dr. Donald HealeyChief Technology Officer$2.1m
- Mr. Blake AftabChief Scientific Officer$1.5m
- Dr. Julie MaltzmanChief Medical Officer
- Dr. Jeffrey ChodakewitzIndependent Director$80,794
- Mr. Steve DubinIndependent Director$94,794
- Mr. Michael GrissingerIndependent Director$30,104
- Dr. Lloyd KlicksteinIndependent Director, since 2019$95,777
- Ms. Katie PengIndependent Director$83,294
- Dr. Andrew SinclairIndependent Director$91,294
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 45
- Social
- 75
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adicet Bio Inc's pipeline includes ADI-001 targeting CD20 for cancer treatment.
- The company focuses on off-the-shelf allogeneic gamma delta T cell therapies for durable patient activity.
- ADI-002 targets glypican 3 protein (GPC3) for specific tumor targeting in therapies.
Weaknesses
- Adicet Bio Inc has 102 employees, which is relatively small for biotechnology development.
- The company's IPO was on 26 January 2018, indicating a limited market history.
- Adicet Bio Inc's business is focused on a single sector, Health Care, with no diversification.
Opportunities
- The biotechnology sector in the US offers significant growth potential for innovative therapies.
- Adicet Bio Inc's ADI-00x pipeline targets solid tumors and hematological indications for expansion.
- The company's focus on gamma delta T cell therapies aligns with emerging cancer treatment trends.
Threats
- The biotechnology industry faces intense competition from established firms in Health Care.
- Regulatory challenges may delay the approval of new therapies in the US market.
- Market volatility could impact the company's ability to secure funding for development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.